Physician profile
Bilal Ansari
NPI 1386648749
$9,332.21
in general payments reported to CMS, 2019-2025
44 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $616 · 2021: $299 · 2022: $845 · 2023: $1,512 · 2024: $2,170 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Long Term Medical Supply Or Device Loan: $2,113 · Consulting Fee: $1,000 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.81 |
| Long Term Medical Supply Or Device Loan | $2,113.03 |
| Consulting Fee | $1,000.00 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,386.05 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $1,020.00 | 2023-2024 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $865.68 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $564.92 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Astrazeneca Pharmaceuticals LP | $440.83 | 2019-2025 | Imfinzi, Onglyza |
| Beigene USA, INC. | $426.59 | 2021-2024 | Brukinsa |
| Pfizer INC. | $336.54 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $243.13 | 2024-2025 | Erleada, Akeega, Imbruvica |
| Abbvie INC. | $224.57 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $221.12 | 2020-2025 | |
| Emd Serono, INC. | $149.84 | 2020-2023 | Bavencio |
| Genzyme Corporation | $147.67 | 2019-2025 | |
| Amgen INC. | $146.99 | 2019-2023 | Lumakras |
| Regeneron Healthcare Solutions, INC. | $143.42 | 2019-2022 | |
| Stemline Therapeutics INC. | $143.42 | 2025 | Orserdu |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $140.14 | 2025 | Xt Cdx |
| Puma Biotechnology, INC. | $137.25 | 2019-2023 | |
| Ge Healthcare | $135.13 | 2022 | |
| Gilead Sciences, INC. | $133.04 | 2021-2025 | Trodelvy |
| Aurinia Pharma U.S., INC. | $125.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2020 | |
| Kite Pharma, INC. | $124.99 | 2019 | |
| Ethicon INC. | $120.29 | 2024 | Monarch Platform |
| Bayer Healthcare Pharmaceuticals INC. | $107.95 | 2022 | |
| Stryker Corporation | $103.37 | 2024 | Augment Injectable |
| Glaxosmithkline, LLC. | $70.07 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Adaptive Biotechnologies Corporation | $68.86 | 2022 | |
| Lilly USA, LLC | $67.22 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $64.99 | 2021 | |
| Astellas Pharma US INC | $47.99 | 2023-2024 | Padcev |
| Celgene Corporation | $38.97 | 2022-2023 | Opdualag |
| Exelixis INC. | $34.24 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $29.71 | 2024 | Enhertu |
| Array Biopharma INC | $25.15 | 2025 | Braftovi, Tukysa, Mektovi |
| Seagen INC. | $24.56 | 2023 | Tukysa |
| Blue Earth Diagnostics | $23.54 | 2025 | Posluma |
| Taiho Oncology, INC. | $18.98 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.73 | 2025 | |
| Pharmacosmos Therapeutics INC. | $17.34 | 2023 | Monoferric |
| Merck Sharp & Dohme LLC | $16.53 | 2023 | Welireg, Keytruda, Lynparza |
| Iovance Biotherapeutics, INC. | $15.83 | 2025 | Amtagvi |
| Cti Biopharma Corp. | $13.03 | 2023 | Vonjo |
| Acrotech Biopharma INC. | $12.98 | 2023 | Beleodaq |
| Clovis Oncology, INC. | $11.56 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.